WO2008092796A1 - Antitumor combination comprising a morpholinyl anthracycline and an antibody - Google Patents

Antitumor combination comprising a morpholinyl anthracycline and an antibody Download PDF

Info

Publication number
WO2008092796A1
WO2008092796A1 PCT/EP2008/050834 EP2008050834W WO2008092796A1 WO 2008092796 A1 WO2008092796 A1 WO 2008092796A1 EP 2008050834 W EP2008050834 W EP 2008050834W WO 2008092796 A1 WO2008092796 A1 WO 2008092796A1
Authority
WO
WIPO (PCT)
Prior art keywords
receptor
growth factor
morpholinyl anthracycline
antibody inhibiting
antibody
Prior art date
Application number
PCT/EP2008/050834
Other languages
English (en)
French (fr)
Inventor
Maria Cristina Geroni
Original Assignee
Nerviano Medical Sciences S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerviano Medical Sciences S.R.L. filed Critical Nerviano Medical Sciences S.R.L.
Priority to EP08708173A priority Critical patent/EP2109462A1/en
Priority to JP2009546758A priority patent/JP2010516741A/ja
Priority to US12/524,984 priority patent/US20100104566A1/en
Publication of WO2008092796A1 publication Critical patent/WO2008092796A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • salts refers to those salts retaining the biological effectiveness and properties of the parent compound.
  • Such salts include acid addition salts obtained by reaction of the free base of the parent compound with inorganic acids such as hydrochloric, hydrobromic, nitric, phosphoric, sulfuric, and perchloric acid and the like; or with organic acids such as acetic, maleic, methanesulphonic, ethanesulfonic, tartaric, citric, succinic and the like.
  • inorganic acids such as hydrochloric, hydrobromic, nitric, phosphoric, sulfuric, and perchloric acid and the like
  • organic acids such as acetic, maleic, methanesulphonic, ethanesulfonic, tartaric, citric, succinic and the like.
  • nemorubicin is in the form of its hydrochloride salt.
  • Pharmaceutically acceptable carriers and excipients are chosen such that side effects from the pharmaceutical compound are minimized and the performance of the compound is not cancelled or inhibited to such an extent that treatment is ineffective.
  • Pharmaceutically acceptable carriers or excipients to be utilized in the preparation of a pharmaceutical composition according to the invention are well known to people skilled in the art of formulating compounds in a form of pharmaceutical compositions.
  • pharmaceutically acceptable carrier refers to one or more compatible solid or liquid filler, diluent or encapsulating substances which are suitable for administration to mammals including humans.
  • pharmaceutically acceptable excipient refers to any inert substance used as a diluent or vehicle for an active substance(s) that is intentionally added to the formulation of a dosage form.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PCT/EP2008/050834 2007-01-29 2008-01-24 Antitumor combination comprising a morpholinyl anthracycline and an antibody WO2008092796A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP08708173A EP2109462A1 (en) 2007-01-29 2008-01-24 Antitumor combination comprising a morpholinyl anthracycline and an antibody
JP2009546758A JP2010516741A (ja) 2007-01-29 2008-01-24 モルホリニルアントラサイクリンおよび抗体を含む抗腫瘍の組み合わせ
US12/524,984 US20100104566A1 (en) 2007-01-29 2008-01-24 Antitumor combination comprising a morpholinyl anthracycline and an antibody

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07101325.4 2007-01-29
EP07101325 2007-01-29

Publications (1)

Publication Number Publication Date
WO2008092796A1 true WO2008092796A1 (en) 2008-08-07

Family

ID=39283788

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/050834 WO2008092796A1 (en) 2007-01-29 2008-01-24 Antitumor combination comprising a morpholinyl anthracycline and an antibody

Country Status (4)

Country Link
US (1) US20100104566A1 (ja)
EP (1) EP2109462A1 (ja)
JP (1) JP2010516741A (ja)
WO (1) WO2008092796A1 (ja)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066093A2 (en) * 1999-04-29 2000-11-09 Pharmacia & Upjohn S.P.A. Combined preparations comprising morpholine anthracyclines and anticancer agent
WO2006078307A1 (en) * 2005-01-21 2006-07-27 Genentech, Inc. Fixed dosing of her antibodies
US20060275305A1 (en) * 2005-05-13 2006-12-07 Bryant John L HERCEPTIN adjuvant therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2172594B (en) * 1985-03-22 1988-06-08 Erba Farmitalia New morpholino derivatives of daunorubicin and doxorubicin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066093A2 (en) * 1999-04-29 2000-11-09 Pharmacia & Upjohn S.P.A. Combined preparations comprising morpholine anthracyclines and anticancer agent
WO2006078307A1 (en) * 2005-01-21 2006-07-27 Genentech, Inc. Fixed dosing of her antibodies
US20060275305A1 (en) * 2005-05-13 2006-12-07 Bryant John L HERCEPTIN adjuvant therapy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
D'ADAMO D R ET AL: "Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas", JOURNAL OF CLINICAL ONCOLOGY 2005 US, vol. 23, no. 28, 2005, pages 7135 - 7142, XP002478570, ISSN: 0732-183X *
JACKMAN A L ET AL: "The combination of cytotoxic and molecularly targeted therapies - can it be done?", DRUG DISCOVERY TODAY: THERAPEUTIC STRATEGIES, ELSEVIER, vol. 1, no. 4, December 2004 (2004-12-01), pages 445 - 454, XP004694304, ISSN: 1740-6773 *
TRNENY MAREK ET AL: "Rituximab combination with anthracyclin based chemothrapy significantly improved the outcome of young patients with diffuse large B-cell lymphoma inlow as well in high risk subgroups", BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 106, no. 11, 1 November 2005 (2005-11-01), pages 687A, XP009099069, ISSN: 0006-4971 *
YUAN SHENGTAO ET AL: "Anticancer activity of methoxymorpholinyl doxorubicin (PNU 152243) on human hepatocellular carcinoma", ANTI-CANCER DRUGS, RAPID COMMUNICATIONS, OXFORD, GB, vol. 15, no. 6, 1 July 2004 (2004-07-01), pages 641 - 646, XP009099093, ISSN: 0959-4973 *

Also Published As

Publication number Publication date
EP2109462A1 (en) 2009-10-21
US20100104566A1 (en) 2010-04-29
JP2010516741A (ja) 2010-05-20

Similar Documents

Publication Publication Date Title
US20100190736A1 (en) Morpholinyl anthracycline derivative combined with protein kinase inhibitors
Iwase et al. A phase II multi-center study of triple therapy with paclitaxel, S-1 and cisplatin in patients with advanced gastric cancer
CN111132696A (zh) Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途
JP6591665B2 (ja) Ｔ−ｄｍ１難治性がん患者のｓｙｄ９８５処置
US20110021517A1 (en) Antitumor combination comprising a morpholinyl anthracycline derivative and demethylating agents
US20100104566A1 (en) Antitumor combination comprising a morpholinyl anthracycline and an antibody
CA2519289A1 (en) Nemorubicin as radiosensitizer in combination with radiation therapy against tumors
AU2004222527A1 (en) Combined therapy comprising nemorubicin and a cyclooxygenase-2-inhibitor
EP1868599B1 (en) Antitumor combination comprising substituted acryloyl distamycin derivatives and antibodies inhibiting growth factors or their receptors
RU2524309C1 (ru) Способ выбора тактики лечения местно-распространенного рака предстательной железы
WO2021224381A1 (en) Combination therapy for treating cancer
Wakelee et al. Novel approaches for the treatment of small cell lung cancer
CN114126656A (zh) 治疗癌症的方法和用途
Panek et al. P08. 46 Synergistic Therapeutic Efficacy via Immunomodulatory Platelet Rich Fibrin Patch (PRF-P) in Combination with Oncolytic Adenovirus for the Treatment of Glioma
KR20220041884A (ko) 전신 투여용 종양용해성 단순 포진 바이러스를 포함하는 약학적 조성물
CA2516097A1 (en) A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent
WO2008140751A1 (en) Human leiosarcoma and non small cell lung cancer lung xenograft models

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08708173

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009546758

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008708173

Country of ref document: EP